GENB Generate Biomedicines (GENB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0002100782
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter
What the filings say about GENB
Planned sales (Form 144), 90 days
$536.6K
2 notices
Generate Biomedicines insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Generate Biomedicines, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3.5% of the 572,707 shares held after it.
- 5 other insiders bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Nally Michael bought about $240.0K of GENB on Mar 4, 2026; 5 other insiders bought within 30 days and 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 300 shares held after it.
- 5 other insiders bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief People Officer Grous Beth bought about $4.8K of GENB on Mar 2, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,000 shares held after it.
- 5 other insiders bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CFO Silvers Jason bought about $16.0K of GENB on Mar 2, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 500 shares held after it.
- 5 other insiders bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CFO Silvers Jason bought about $8.0K of GENB on Mar 2, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,562,500 shares held after it.
- 5 other insiders bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Nutritional Health LTP Fund General Partner LLC bought about $25.0M of GENB on Mar 2, 2026, the largest insider purchase at the company on our record; 5 other insiders bought within 30 days and 68 funds added in the latest 13F quarter.7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 55% of Pharma & Biotech
Revenue
-37.7% year over year (latest quarter)
below 75% of Pharma & Biotech
Margin
-1065.2% net margin (latest quarter)
below 86% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
14.8% of the float short (float per yahoo 2026-10-27) · 8.0 days to cover · settled 2026-10-15
more than 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GENB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-2.4%12M
Insider buyForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GENB: institutional holders (13F)
13F holdings, latest reported quarter
62,673,117 sh
$1.1B
5,221,599 sh
$88.1M
4,215,632 sh
$71.1M
3,283,844 sh
$55.4M
2,094,616 sh
$35.3M
Congress trades in GENB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GENB planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
ARNOLD FRANCES
Filed 2026-09-02
$520.6K
ARNOLD FRANCES
Filed 2026-09-01
$16.0K
GENB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$17.3M position · as of 2026-07-31
1.1%
Virtus Biotech Clinical Trials Etf
$351.5K position · as of 2026-07-31
0.8%
Eaton Vance Worldwide Health Sciences Fund
$4.1M position · as of 2026-05-31
0.5%
U.S. Small and Mid Cap Equity Fund
$452.8K position · as of 2026-06-30
0.4%
JPMorgan Small Cap Growth Fund
$9.8M position · as of 2026-06-30
0.4%
American Funds U.S. Small & Mid Cap Equity Fund
$2.3M position · as of 2026-05-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
3 active
2
Phase 3
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 68 funds added last quarter, $536.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
GENB financials
Revenue growth
-37.7%
XBRL, annual
Net margin
-1065.2%
GENB Stock Sonar score 3/7 axes
Find similar shapesCompareGENB ranks highest on institutional and government (55th percentile) and growth (25th), and lowest on risk and compliance (25th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GENB filings, in plain words
Are there planned insider sales of GENB?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $536.6K of stock; the latest, by ARNOLD FRANCES, was filed 2026-09-02.
Read the full summary
Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $536.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
